Mosaic Data Science’s Post

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 #𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 #𝘁𝗿𝗶𝗮𝗹𝘀: Carelane, a life sciences technology start-up, has announced the successful closure of its pre-seed funding round, raising €800,000. The investment, led by HTGF | High-Tech Gründerfonds (HTGF), will fuel the expansion of its unified platform designed to streamline clinical trials, significantly reducing the operational burdens faced by pharmaceutical companies, contract research organizations, and academic researchers. Clinical trials today face inefficiencies and high costs because they are reliant on multiple disjointed software systems for essential tasks such as data management, eConsent, tokenization, sample tracking, drug supply, and patient follow-up. The time required for integration and the challenges of process orchestration, along with regulatory compliance demands for unified audit trails, further complicate the situation. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/dzWuBz6V Gustav V., Yannick Boerner, Dr. Baltrukovich Natalya, MBA, PhD, Tobias Jacob

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

Interview: Digital Transformation Has Revolutionized The Way Clinical Trials Are Conducted, Leading To Superior Outcomes - https://lnkd.in/gXyGX5xV - Aiswariya Chidambaram helps pharmaceutical companies and emerging biotech firms strategize their vision and roadmap.

Unlocking the full potential of clinical research management requires a strategic shift towards a platform-based approach. But why is this approach so vital? 🤔 From centralized data management to integrated compliance and governance, and enhanced collaboration, discover how this shift can transform the way you conduct clinical research. Explore the power of a platform-based transformation here: https://hubs.li/Q02p8Ksq0 Sign up for our webinar: "From Legacy to Leading Edge: Embracing Next-Gen CTMS" on Thursday, March 28 2024, at 11 AM EST: https://hubs.li/Q02p8Ksr0 #CTMS #eTMF #EDC #RTSM #Safety #PV #Pharmaceutical #Biotechnology #MedicalDevices #Diagnostics #Cloudbyz #ClinicalTrials

Data: most of us have a lot of it, but do we know what to do with it? ❓❓❓ Clinical trial data provides vital insight into patient populations, treatment outcomes, adverse reactions, and comparative effectiveness. This blog post explains 4 key ways pharma companies can make their data work for them: https://hubs.la/Q02r9J3h0 #Data #Pharma

Hi Network!    Even though, surprisingly, (even after the COVID-19 pandemic), the DCT approach in clinical trials is not as popular as expected, I personally consider this topic interesting to explore and thus thought that maybe some of you would be interested in reading one more study about the current state of decentralized clinical trials. The study below gives reasons why some organizations implement DCT and what about others that don’t.   The study is based on the survey results better to understand the current state of DCT adoption and implementation. The three crucial factors were examined: organization size, technology adoption, and patient involvement.   The most interesting results are as follows, first I quote:     “There is a significant relationship (p ≈ 0.0475) between the size of an organization and its implementation of DCTs. Larger organizations are more likely to have adopted DCTs..” This is closely connected with the availability of resources and needed infrastructure for efficient implementation. The survey also highlights that technology vendors and CROs have more belief in technology as a critical factor for DCT success than biopharmaceutical companies. The study also evaluates approaches for trials the organizations use and the role of DCT.   While DCT adoption is not widespread due to clear reasons, I think the right balance between technology and the specifics of a particular organization can ensure DCT adoption for fast, efficient and diverse trials. For instance, leveraging scalable cloud-based platforms can enable small and mid-sized companies to manage and conduct DCT without significant upfront investment in infrastructure. Advanced data analytics and AI can streamline patient recruitment, monitoring, and data analysis, making the trial process more efficient and cost-effective.    💬 What are your thoughts on the survey results indicating a significant relationship between organization size and DCT implementation? https://lnkd.in/dSXDrf7n #clinicaltrials #DCT

In case you missed it - our most recent article in FirstWord Pharma is live! Co-authored by Noah Pines and Tim Brewer, they explore how leveraging market research early in the development process can optimize clinical trials. Check it out here! #pharma #mrx #clinicaltrials https://lnkd.in/g88M6fTM

Uncovering new trends within the clinical trial supply chain At our upcoming Clinical Trial Supply New England 2024 conference we will gather pharma and biotech colleagues to discuss what’s to come for the clinical trial supply industry. - https://lnkd.in/dvdkzYki #clinicaltrials #clinicaltrialsupply #clinicaltrialsupplychain #supplychain #pharmasupplychain #pharmalogistics